Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Hetrombopag Olamine Tablets compared to a placebo in patients with thrombocytopenia caused by chemotherapy. The study focuses on patients who have solid tumors and experience low platelet counts due to chemotherapy treatment. This phase III trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and aims to better understand treatment options for chemotherapy-induced thrombocytopenia. Participants receive treatments in two parts in Part A, all participants are given Hetrombopag Olamine. In Part B, participants are randomly assigned to receive either Hetrombopag Olamine or a matching placebo. Treatments are given during chemotherapy cycles that occur every 14 or 21 days. The study includes monitoring over approximately 3 years to assess platelet counts and the need for rescue therapies. During the study, participants undergo regular monitoring of platelet levels, safety labs, and vital signs. Researchers track whether participants maintain platelet counts sufficient to continue chemotherapy without delay or modification. Outcomes include measuring platelet count improvements, bleeding events, and adverse reactions. The overall participation lasts up to about three years, with ongoing assessment of chemotherapy cycle completion and treatment safety.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.
Actively Recruiting
Researchers are evaluating the efficacy and safety of olverembatinib compared to bosutinib in patients with chronic phase chronic myeloid leukemia CML-CP. This phase 3 randomized study includes patients previously treated with at least two tyrosine kinase inhibitors TKIs and also examines olverembatinib in a single-arm group of CML-CP patients with the T315I mutation. The study addresses treatment options for patients with limited effective therapies and includes a crossover option for those meeting failure criteria while on bosutinib. Participants in Part A will be randomly assigned to receive either olverembatinib every other day or bosutinib once daily. Part B involves patients with the T315I mutation receiving olverembatinib alone. Treatment cycles are 28 days, with pharmacokinetic assessments after the first two cycles. Patients may continue treatment and be monitored for up to five years to evaluate long-term outcomes and safety. During the study, participants will undergo assessments including molecular response rates at 24 and 96 weeks, cytogenetic response evaluations at multiple intervals, and monitoring for adverse events. Researchers will also track progression-free and overall survival. Organ function and performance status will be regularly evaluated to ensure safety and treatment adherence throughout the study duration.